Skip to main content

Research Repository

Advanced Search

All Outputs (73)

Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service (2024)
Journal Article
Radford, S. J., Abdul-Aema, B., Tench, C., Leighton, P., Coad, J., & Moran, G. W. (2024). Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service. Scandinavian Journal of Gastroenterology, https://doi.org/10.1080/00365521.2024.2330588

Background Imaging is used to monitor disease activity in small bowel Crohn’s disease (CD). Magnetic Resonance Enterography is often employed as a first modality in the UK for assessment and monitoring, however waiting times, cost, patient burden an... Read More about Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.

Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review (2024)
Journal Article
Egiz, A. M. A. M., Sinopoulou, V., Abousaleh, Gordon, M., Moran, G. W., Phlananthachai, S., …Al-Tameemi, A. H. A. (2024). Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review. BMJ Open Gastroenterology, 11(1), Article e001334. https://doi.org/10.1136/bmjgast-2023-001334

Introduction Randomised controlled trials (RCTs) of key therapies in inflammatory bowel disease (IBD) are often presented and available as abstracts for significant periods of time prior to full publication, often being employed to make strategic and... Read More about Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review.

Infliximab for maintenance of medically-induced remission in Crohn's disease (2024)
Journal Article
Gordon, M., Sinopoulou, V., Sarian, A., Akobeng, A. K., & Moran, G. W. (2024). Infliximab for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews, 2(2), Article CD012609. https://doi.org/10.1002/14651858.CD012609.pub2

BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha (TNF-α) which is present in high levels in the blood serum, mucosa and stool of patients with Crohn's disease. OBJECTIVES: To determine the effica... Read More about Infliximab for maintenance of medically-induced remission in Crohn's disease.

Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial (2024)
Journal Article
Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J., D’Haens, G. R., …Feagan, B. G. (2024). Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterology, 11(1), Article e001218. https://doi.org/10.1136/bmjgast-2023-001218

Introduction: Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, com... Read More about Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial (2024)
Journal Article
Lindsay, J. O., Hind, D., Swaby, L., Berntsson, H., Bradburn, M., Bannur C, U., …Snowden, J. A. (2024). Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9(4), 333-345. https://doi.org/10.1016/s2468-1253%2823%2900460-0

Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy... Read More about Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study (2024)
Journal Article
Azam, A. S., Tsang, Y., Thirlwall, J., Kimani, P. K., Sah, S., Gopalakrishnan, K., …Snead, D. R. J. (2024). Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study. Histopathology, 84(5), 847-862. https://doi.org/10.1111/his.15129

Aims: To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods: A total of 2024 cases (608 breast, 607 GI, 6... Read More about Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study.

An examination of resting-state functional connectivity in patients with active Crohn’s disease (2023)
Journal Article
Thapaliya, G., Eldeghaidy, S., Radford, S. J., Francis, S. T., & Moran, G. W. (in press). An examination of resting-state functional connectivity in patients with active Crohn’s disease. Frontiers in Neuroscience, 17, Article 1265815. https://doi.org/10.3389/fnins.2023.1265815

Background: Alterations in resting state functional connectivity (rs-FC) in Crohn’s Disease (CD) have been documented in default mode network (DMN) and frontal parietal network (FPN) areas, visual, cerebellar, salience and attention resting-state-net... Read More about An examination of resting-state functional connectivity in patients with active Crohn’s disease.

An examination of resting-state functional connectivity in patients with active Crohn's disease (2023)
Journal Article
Francis, S. T., Moran, G. W., Eldeghaidy, S., Radford, S., & Thapaliya, G. (2023). An examination of resting-state functional connectivity in patients with active Crohn's disease. Frontiers in Neuroscience, 17, Article 1265815. https://doi.org/10.3389/fnins.2023.1265815

Background: Alterations in resting state functional connectivity (rs-FC) in Crohn’s Disease (CD) have been documented in default mode network (DMN) and frontal parietal network (FPN) areas, visual, cerebellar, salience and attention resting-state-net... Read More about An examination of resting-state functional connectivity in patients with active Crohn's disease.

Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource (2023)
Journal Article
Kapizioni, C., Desoki, R., Lam, D., Balendran, K., Al-Sulais, E., Subramanian, S., …Raine, T. (in press). Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource. Journal of Crohn's and Colitis, Article jjad203. https://doi.org/10.1093/ecco-jcc/jjad203

Background and Aims To compare effectiveness of different biologic therapies and sequences in patients with Inflammatory Bowel Disease (IBD) using real-world data from a large cohort with long exposure. Methods Demographic, disease, treatment an... Read More about Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource.

Evolution of Treatment Targets in Inflammatory Bowel Disease (2023)
Journal Article
Kyriacou, M., Vuyyuru, S., & Moran, G. (2023). Evolution of Treatment Targets in Inflammatory Bowel Disease. Medical Research Archives, 11(11), https://doi.org/10.18103/mra.v11i11.4662

Inflammatory Bowel Disease (IBD), which encompasses Crohn's disease and ulcerative colitis, represents a chronic and progressive condition characterised by periods of active inflammation interspersed with periods of remission. The r... Read More about Evolution of Treatment Targets in Inflammatory Bowel Disease.

Systematic Review: Sarcopenia in paediatric inflammatory bowel disease (2023)
Journal Article
Aljilani, B., Tsintzas, K., Jacques, M., Radford, S., & Moran, G. W. (2023). Systematic Review: Sarcopenia in paediatric inflammatory bowel disease. Clinical Nutrition ESPEN, 57, 647-654. https://doi.org/10.1016/j.clnesp.2023.08.009

Background: Low skeletal muscle mass (MM) and deteriorated function (sarcopenia) can be a frequent complication in paediatric inflammatory bowel disease (IBD). Aim: To conduct a systematic review of the paediatric IBD literature on skeletal muscle fu... Read More about Systematic Review: Sarcopenia in paediatric inflammatory bowel disease.

Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis (2023)
Journal Article
Aruljothy, A., Singh, S., Narula, N., Moran, G. W., Vuyyuru, S. K., Hogan, M., …Jairath, V. (2023). Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. Alimentary Pharmacology and Therapeutics, 58(8), 740-762. https://doi.org/10.1111/apt.17666

Background: Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat. Aim: To assess the efficacy of medical treatments for UP. Methods: We searched MEDLINE, EMBASE, and CENTRAL on 23 November... Read More about Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.

Stakeholder-identified barriers and enablers to ultrasound implementation in inflammatory bowel disease services in the UK: a qualitative interview study. (2023)
Journal Article
Radford, S., Leighton, P., Coad, J., & Moran, G. (2023). Stakeholder-identified barriers and enablers to ultrasound implementation in inflammatory bowel disease services in the UK: a qualitative interview study. BMJ Open, 13(6), Article e067528. https://doi.org/10.1136/bmjopen-2022-067528

The study sought to explore and better understand the perceptions and experiences of stakeholders in relation to the use of ultrasound for the assessment of inflammatory bowel disease (IBD) in adults in the UK. A qualitative semistructured interview... Read More about Stakeholder-identified barriers and enablers to ultrasound implementation in inflammatory bowel disease services in the UK: a qualitative interview study..

MRI tagging of colonic chyme mixing in healthy subjects: Inter‐observer variability and reliability of the measurement with time (2023)
Journal Article
Alshammari, M. T., Alyami, A. S., Wilkinson-Smith, V., Spiller, R. C., Gowland, P., Marciani, L., …Hoad, C. L. (2023). MRI tagging of colonic chyme mixing in healthy subjects: Inter‐observer variability and reliability of the measurement with time. Neurogastroenterology and Motility, 35(8), Article e14610. https://doi.org/10.1111/nmo.14610

Background: Magnetic resonance imaging (MRI) tagging techniques have been applied to the GI tract to assess bowel contractions and content mixing. We aimed to evaluate the dependence of a tagging measurement (for assessing chyme mixing) on inter-obse... Read More about MRI tagging of colonic chyme mixing in healthy subjects: Inter‐observer variability and reliability of the measurement with time.

BSG 2024 IBD guidelines protocol (standard operating procedures) (2023)
Journal Article
Darie, A., Sinopoulou, V., Ajay, V., Bel Kok, K., Patel, K. V., Limdi, J., …Gordon, M. (2023). BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterology, 10(1), Article e001067. https://doi.org/10.1136/bmjgast-2022-001067

Introduction In the past 5 years, there have been several advances in the management of inflammatory bowel disease (IBD). We aim for a new guideline to update the most recent guideline published in 2019. We present the prospective operating procedure... Read More about BSG 2024 IBD guidelines protocol (standard operating procedures).

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study (2022)
Journal Article
Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., …Powell, N. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145-156. https://doi.org/10.1016/S2468-1253%2822%2900389-2

Background Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutr... Read More about Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease (2022)
Journal Article
Thapaliya, G., Eldeghaidy, S., Asghar, M., McGing, J., Radford, S., Francis, S., & Moran, G. W. (2022). The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease. Brain Imaging and Behavior, https://doi.org/10.1007/s11682-022-00742-6

Alterations in grey matter volume (GMV) and cortical thickness (CT) in Crohn’s disease (CD) patients has been previously documented. However, the findings are inconsistent, and not a true representation of CD burden, as only CD patients in remission... Read More about The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease.

Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease (2022)
Journal Article
Ellul, P., Schembri, J., Vella Baldacchino, A., Molnár, T., Resal, T., Allocca, M. A., …Katsanos, K. (2023). Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 17(4), 489-496. https://doi.org/10.1093/ecco-jcc/jjac169

BACKGROUND AND AIMS: Post-inflammatory polyps [PIPs] are considered as indicators of previous episodes of severe inflammation and mucosal ulceration. Inflammatory bowel disease [IBD], namely Crohn's disease [CD] and ulcerative colitis [UC], exhibit a... Read More about Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease.

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study (2022)
Journal Article
Saifuddin, A., Kent, A. J., Mehta, S. J., Hicks, L. C., Gonzalez, H. A., Segal, J. P., …PREPARE‐IBD Collaborators. (2022). Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 56(10), 1460-1474. https://doi.org/10.1111/apt.17223

Background: The COVID-19 pandemic offered a unique opportunity to understand inflammatory bowel disease (IBD) management during unexpected disruption. This could help to guide practice overall. Aims: To compare prescribing behaviour for I... Read More about Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.

British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance (2022)
Journal Article
Churchhouse, A. M. D., Moffat, V. E. L., Selinger, C. P., Lamb, C. A., Thornton, M. J., Penman, I., & Din, S. (2023). British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance. Gut, 72(9), 1631-1634. https://doi.org/10.1136/gutjnl-2022-328309